维普中文期刊产品整合服务
29篇 您的检索式:作者名="Salut"
    题名 作者 年代 出处 被引量
1Magnetic spin–orbit interaction of light显示文摘We study the directional excitation of optical surface waves controlled by the magnetic field of light.We theoretically predict that a spinning magnetic dipole develops a tunable unidirectional coupling of light to transverse electric(TE)polarized Bloch surface waves(BSWs).Experimentally,we show that the helicity of light projected onto a subwavelength groove milled into the top layer of a 1D photonic crystal(PC)controls the power distribution between two TE-polarized BSWs excited on both sides of the groove.Such a phenomenon is shown to be solely mediated by the helicity of the magnetic optical field,thus revealing a magnetic spin-orbit interaction of light.Remarkably,this magnetic optical effect is clearly observed via a near-field coupler governed by an electric dipole moment:it is of the same order of magnitude as the electric optical effects involved in the coupling.This opens up new degrees of freedom for the manipulation of light and offers desirable and novel opportunities for the development of integrated optical functionalities.Mengjia Wang Hongyi Zhang Tatiana Kovalevich Roland Salut Myun-Sik Kim Miguel Angel Suarez Maria-Pilar Bernal Hans-Peter Herzig Huihui Lu Thierry Grosjean 2018Light(Science & Applications)2018,7,1:15
2A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer显示文摘Cristina Gravalos Antonieta Salut Carlos García-Girón Rocío García-Carbonero Ana León Isabel Sevilla Joan Maurel Beatriz Esteban Eduardo García-Rico Adolfo Murias Hernán Cortés-Funes 2012Clinical and Translational Oncology2012,,8:2
3A randomized phaseⅡstudy to compare oxaliplatin plus 5-fluorouracil and leucovorin(FOLFOX4)versus oxaliplatin plus raltitrexed(TOMOX)as first-line chemotherapy for advanced colorectal cancer显示文摘GRAVALOS C SALUT A GARCA-GIRN C 2012Clin Transl Oncol2012,14,8:1
4Resonant optical transmission through sub-wavelength annular apertures caused by a plasmonic transverse electromagnetic(TEM) mode显示文摘NDAO A SALVI J SALUT R 2014Journal of Optics2014,16,12:1
5The role of magnetic resonance angiography in the diagnosis of subclavian steal显示文摘Carriero A Salute L Tartaro A 1995Cardiovasc Intervent Radiol1995,18,2:1
6A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil显示文摘Méndez M Salut A García Girón C 2003Clin Colorectal Cancer2003,3,3:1
7A randomized phase Ⅱ study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer显示文摘Gravalos C Salut A Garcia-Giron C 2012Clin Transl Oncol2012,14,8:1
8Macro-and micronutrient effects on decomposition of leaf litter from two tropical tree species:inferences from a short-term laboratory incubation显示文摘POWERS J S SALUTE S 2011Plant and Soil2011,346,:1
9A randomized phaseⅡstudy to compare oxaliplatin plus 5-fluorouracil and leucovorin(FOLFOX4)versus oxaliplatin plus raltitrexed(TOMOX)as first-line chemotherapy for advanced colorectal cancer显示文摘Gravalos C Salut A Garcl′a-Giro′n C 2012Clin Transl Oncol2012,14,8:1
10A randomized phase i1 study to compare oxaliplatin plus 5 - fluorouracil and leucovorin ( FOL- FOX4 ) versus oxaliplatin plus raltitrexed ( TOMOX ) as first- linechemotherapy for advanced colorectal cancer 显示文摘Gravalos C Salut A Garcia - Giron C 2012Clin Transl Onco12012,14,8:1
11A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leuco- vorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer显示文摘Gravalos C Salut A Garcia-Gir6n C 2012Clin Transl Oncol2012,14,8:1
12A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first- line chemotherapy for advanced colorectal cancer显示文摘Gravalos C Salut A Garcia-Giron C 2012Clin Transl Oncol2012,14,8:1
13Manufacture of microfluidic glass chips by deep plasma etching,femtosecond laser ablation, and anodic bonding显示文摘Queste S Salut R Clatot S 2010Mi- crosystem Technologies2010,16,6:1
14Urbanization and Fertility: An Event-history Analysis of Coastal Ghana显示文摘Michael J White Salut Muhidin Catherine Andrzejewski Eva Tagoe Rodney Knight Holly Reed 2008Demography2008,45,4:1
15A randomizedphase II study to compare oxaliplatin plus 5-fiuorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer显示文摘Gravalos C Salut A Garcia-Gir6n C 2012Clin Transl Oncol2012,14,8:1
16A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin(FOLFOX4)versus oxaliplatin plus raltitrexed(TOMOX)as first-line chemotherapy for advanced colorectal cancer显示文摘Gravalos C Salut A Garcia-Giron C 2012Clin Transl Oncol2012,14,8:1
17A randomized phase Ⅱ study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxalipl- atin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer 显示文摘GRAVALOS C SALUT A GARCA-GIR6N C 2012Clin Transl Oncol2012,14,8:1
18Optimal nonlinear filtering in GPS/INS integration显示文摘Carvalho H Moral P D Monin A Salut G 1997IEEE Transactions on Aerospece and Electronic Systems1997,33,3:1
19A randomized phase Ⅱ study to compare oxaliplatin plus 5-fluorouracil and leucovorin(FOLFOX4)versus oxaliplatin plus raltitrexed(TOMOX)as first-line chemotherapy foradvanced colorectal cancer 显示文摘GRAVALOS C SALUT A GARCIA-GIRON C 2012Clin Transl Oncol2012,14,8:1
20A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin ( FOLFOX4 ) versus oxaliplatin plus raltitrexed ( TOMOX ) as first-line chemotherapy for advanced colorectalcancer 显示文摘Gravalos C Salut A Garcfa-Gir6n C 2012Clin Transl Oncol2012,14,:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费